Enjoy complimentary customisation on priority with our Enterprise License!
The Global Human Microbiome Therapeutics Market size is forecast to increase by USD 732.95 million at a CAGR of 30.11% between 2022 and 2027.
The growth of the market depends on several factors, including the growing prevalence of chronic diseases, the robust pipeline in the human microbiome therapeutics market, and the side effects of existing treatments for health disorders. Challenges such as indiscriminate use of antibiotics, lack of trained professionals in the pharmaceutical industry, and differences in dietary habits and use of medicines will hamper the growth of the market. Nevertheless, market trends such as the increase in industry-academia collaboration for the development of novel therapeutics, increasing investments in human microbiome therapeutics, and increasing partnerships in the human microbiome therapeutics market will influence the growth of the market. This market analysis and report also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
| Study Period | 2023 |
| Base Year For Estimation |
2022 |
| CAGR | 30.11% |
| Forecast period |
2023-2027 |
| Fastest Growing Region |
North America at 41% |
| List of Table and Charts |
175 |
The market is driven by partnerships leveraging diverse competence in microbiology, encompassing microorganisms like bacteria, viruses, fungi, and bacteriophages. These therapeutics target human cells and the immune system, influencing vital processes like food digestion and disease defense. With a focus on clinical trial research and preclinical investigations, they offer promising avenues for vulnerable individuals seeking innovative treatments. Collaborations between stakeholders are key to unlocking the potential of microbiome-based therapies, paving the way for advancements in healthcare.The market is driven by partnerships leveraging diverse competence in microbiology, encompassing microorganisms like bacteria, viruses, fungi, and bacteriophages. These therapeutics target human cells and the immune system, influencing vital processes like food digestion and disease defense. With a focus on clinical trial research and preclinical investigations, they offer promising avenues for vulnerable individuals seeking innovative treatments. Collaborations between stakeholders are key to unlocking the potential of microbiome-based therapies, paving the way for advancements in healthcare.
In company offerings, we provide an in-depth analysis of 20 top company profiles, along with other valuable insights comprising of:
• Company Overviews
• Key News and Updates
• Products and Services
• Market-leading Offerings
• Focused Segments
4D Pharma Plc - The company offers human microbiome such as MicroRx.
The following are the leading companies in the market. These companies are adopting various strategies, including strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to strengthen their market presence. Collectively, they hold the largest market share and set industry trends.
In the global market, the product segment encompasses a wide array of microbiome-based medicines and diagnostic devices. These products are at the forefront of medication development, leveraging enzymes and technological advancements to address various health challenges. Research grants fuel innovation in this segment, enabling the development of therapeutics targeting conditions such as chronic hepatitis B and infectious diseases. With a growing understanding of microbial dysbiosis and its implications for human health, there's an increasing focus on early diagnosis and personalized prescriptions. Therapeutics in this segment aim to restore microbial balance and promote human health by addressing the root causes of diseases linked to microbiome imbalances. As antibiotic usage evolves, these innovative products offer promising alternatives, paving the way for a new era in healthcare.
Based upon Product, the market share of the probiotic segment is estimated to witness significant growth during the forecast period.
Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. Probiotics are bacteria and yeast that help maintain a healthy microbial balance in the intestines of humans. Probiotics are generally found in yogurt and other fermented foods.
The probiotics segment was the largest segment and was valued at USD 25.89 million in 2017. Probiotic supplements are a way to add good bacteria to the body, as they contain certain health benefits, such as destroying disease-causing cells, producing vitamins, and helping digestion. They also enhance the immune system and protect proteins and lipids from oxidation damage.
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The human microbiome therapeutics market in North America is expected to experience a double-digit growth rate, but it is expected to be slower than in Europe and Asia. Factors such as significant investments in R&D for the development of novel therapeutic techniques and high incidences of gastrointestinal and metabolic disorders and immunological disorders drive the market in the region.
The market is witnessing significant growth propelled by partnerships and technological advancements. It explores the intricate interactions of microorganisms, including bacteria, viruses, and fungi, with human cells and the immune system. Through innovative therapies, it addresses various health aspects, from food digestion to disease defense, benefiting vulnerable individuals. With a focus on chronic hepatitis B and infectious diseases, microbiome-based medicines offer promising avenues for medication development. These therapies combat microbial dysbiosis and promote early diagnosis, reducing antibiotic usage and advancing personalized prescriptions. Supported by research grants, they pave the way for transformative therapeutics, revolutionizing human health. Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of chronic diseases is driving growth in the human microbiome therapeutics market. The growing global prevalence of chronic diseases, such as diabetes, hypertension, and obesity, is the major driver for market growth. These diseases, in turn, result in the development of other serious diseases. High blood pressure is also likely to be caused by bad lifestyle habits and genetic factors. No symptoms are usually caused by hypertension. There has been a growing body of evidence suggesting an association between alterations in the human microbiome and hypertension. Therefore, there is a need to develop Microbiome therapeutics in response to the symptoms and treatment of hypertension.
Studies have shown that middle-aged, obese men have a 50%-60% higher risk of heart failure compared with middle-aged, non-obese men. A great deal of obesity is caused by the gut microbiome. Thus, over the next few years, we will see an increase in efforts to harness and build a human microbiome. Therefore, the increasing prevalence of chronic diseases, which can cause disruptions in normal gut microbiota, will drive the growth of the global human microbiome therapeutics market during the forecast period.
The increase in industry-academia collaboration for the development of novel therapeutics is a primary trend in the microbiome therapeutics market. The key players in the global pharmaceutical drugs market are increasingly extending their support to academic institutions to support the R&D of innovative products for diabetes care. Collaborations between companies and academic institutions enable the amalgamation of the research expertise of academic institutions with the marketing intelligence of pharmaceutical companies.
The funding for conducting trial studies is also generated by such cooperation. The development of new therapeutic approaches, e.g. in the area of Human Microbiome therapeutics, is encouraged by an increasing number of Public Private Partnerships, especially in Developing Countries. The main trend in the coming years is expected to be industry-academia collaboration. The increase in industry-academia collaboration for the development of novel therapeutics will propel the growth of the global human microbiome therapeutics market.
The indiscriminate use of antibiotics is a major challenge faced by the microbiome therapeutics. Antimicrobial resistance, driven by the overuse of antibiotics, is one of the major public health concerns globally. Antibiotic overprescribing is a common problem in primary care, where viruses cause most of the infections. Antibiotic resistance adds considerable cost to the already overburdened healthcare system as it limits the number of drugs available for treatment as well as the efficacy of the existing drugs in the long run.
Moreover, the large number of antibiotics used has been identified as a major challenge for the development of human microbiome therapeutics, although it is not related to physiology or demographic factors. The use of antibiotics can be life savers for a number of fungal infections. However, indiscriminate antibiotic use has a negative effect on the natural flora of our body and affects the function of microbial therapeutic agents. Therefore, negative effects associated with the indiscriminate use of antibiotics will be a challenge to the growth of the global market during the forecast period.
The market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Human Microbiome Therapeutics Market Customer Landscape
In the realm of healthcare, the market emerges as a frontier of innovation, driven by partnerships and a commitment to competence. With a focus on leveraging the potential of bacteriophages, fungi, viruses, and protozoa, researchers explore the intricate interactions within the microbiome and their implications for human health. From understanding food digestion to enhancing disease defense mechanisms, clinical trial research delves into microbiome-based medicines. Particularly, vulnerable individuals benefit from preclinical investigations, paving the way for virtual and decentralized clinical trials. Technological advancements bolster medication development and diagnostic devices, enabling early diagnosis of conditions like chronic hepatitis B. By addressing microbial dysbiosis and optimizing antibiotic usage, these therapies hold promise for improving human health globally.
The market is witnessing significant growth, driven by groundbreaking research and the exploration of human cells and enzymes. With substantial funding from research grants, scientists delve into the intricate relationships between the microbiome and various health conditions, including infectious diseases. As a result, new therapeutic approaches are emerging, offering promising alternatives to traditional prescriptions. Businesses are investing in the development of medicinal drugs targeting the microbiome, despite government limitations in some regions. Notably, research activity in areas like autistic spectrum disorder (ASD) is on the rise, fueled by increased awareness and funding opportunities. These advancements signify a transformative era in healthcare, where microbiome-based therapies hold immense potential for addressing a wide range of health concerns globally.
The market is witnessing a revolutionary shift in healthcare, driven by advancements in diagnostic instruments and the infectious disease diagnostics industry. With a deeper understanding of the microbial population and immunity, scientists are developing medicines that target the microbiota, ushering in a new therapy era. Collaboration between clinicians and researchers is paramount in exploring GI indications such as C. difficile infection and addressing challenges like antimicrobial resistance genes. Microbiome research, including fecal microbiota therapy (FMT),Microbiome Sequencing , is gaining momentum, especially in conditions like Crohn's disease. Regulatory frameworks and approval processes are evolving to accommodate innovative microbiome drugs, fostering growth opportunities for small and medium-sized enterprises (SMEs). This collaborative effort between academia, industry, and regulators underscores the potential of natural and holistic approaches in shaping the future of healthcare.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
159 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 30.11% |
|
Market growth 2023-2027 |
USD 732.95 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
28.29 |
|
Regional analysis |
North America, Europe, Asia, and Rest of the World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Germany, France, UK, and Japan |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc. |
|
Market dynamics |
Market trends and analysis, Market growth and trends and inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.